To include your compound in the COVID-19 Resource Center, submit it here.
Updated data from 33 evaluable patients in an ongoing, open-label, dose-escalation, U.S. Phase I trial showed that twice-weekly SF1126
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury